Streptonigrin

Streptonigrin

SCHEMBL3940

COC1=C(N)C(=O)c2nc(-c3nc(C(=O)O)c(C)c(-c4ccc(OC)c(OC)c4O)c3N)ccc2C1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 1.00
LMNA P02545 3/20 1.00
SMN1; SMN2 Q16637 3/20 1.00
NPC1 O15118 3/20 1.00
RAB9A P51151 3/20 1.00
POLB P06746 2/20 1.00
MAPK1 P28482 2/20 1.00
MEN1 O00255 2/20 1.00
KMT2A Q03164 2/20 1.00
PDE4A P27815 2/20 1.00
PDE4B Q07343 2/20 1.00
PDE4C Q08493 2/20 1.00
PDE4D Q08499 2/20 1.00
PADI1 Q9ULC6 2/20 1.00
PADI3 Q9ULW8 2/20 1.00
PADI4 Q9UM07 2/20 1.00
PADI2 Q9Y2J8 2/20 1.00
KDM4E B2RXH2 1/20 1.00
TGM2 P21980 1/20 1.00
GALK1 P51570 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Streptonigrin SCHEMBL29374011 1.00 MAPT (1.00) MAPTLMNASMN1; SMN2NPC1RAB9A
Streptonigrin SCHEMBL29821157 1.00 MAPT (1.00) MAPTLMNASMN1; SMN2NPC1RAB9A
Streptonigrin SCHEMBL29371276 1.00 MAPT (1.00) MAPTLMNASMN1; SMN2NPC1RAB9A
SCHEMBL25015126 0.93 MAPT (0.87) MAPTLMNASMN1; SMN2NPC1RAB9A
SCHEMBL30260509 0.93 MAPT (0.87) MAPTLMNASMN1; SMN2NPC1RAB9A
Streptonigrin SCHEMBL23421492 0.92 LMNA (0.85) MAPTLMNASMN1; SMN2NPC1RAB9A
Streptonigrin SCHEMBL6299739 0.91 LMNA (0.84) MAPTLMNASMN1; SMN2NPC1RAB9A
SCHEMBL23484220 0.89 FNTA (0.82) MAPTLMNASMN1; SMN2NPC1RAB9A
SCHEMBL20257205 0.85 SMN1; SMN2 (0.75) MAPTLMNASMN1; SMN2NPC1RAB9A
SCHEMBL29885591 0.82 LMNA (0.70) MAPTLMNASMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 43745 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4748859-A2 CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF The Regents of the University of California (US) 2026-05-27 EP claimed
US-20260115305-A1 LINKERS, CONJUGATES AND APPLICATIONS THEREOF GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) 2026-04-30 US claimed
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-04-30 US claimed
US-20260108619-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2026-04-23 US claimed
US-20260085100-A1 METHODS OF ANTIGEN PRODUCTION THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2026-03-26 US claimed
US-20260077056-A1 LINKER-PAYLOAD COMPOUND, CONJUGATES AND APPLICATIONS THEREOF GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) 2026-03-19 US claimed
US-12576124-B2 Formulation of a conjugate of a tubulysin analog to a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD (CN) 2026-03-17 US claimed
EP-4698185-A1 METHODS AND SYSTEMS FOR IMPROVING ANTI-CANCER THERAPIES Osasuna Therapeutics SA (CH) 2026-02-25 EP claimed
EP-4694935-A1 COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ANTI-PD-1 ANTIBODY, AND USE THEREOF Genequantum Healthcare (Suzhou) Co., Ltd. (CN) 2026-02-18 EP claimed
EP-4694909-A1 METHODS OF MODULATING THE EPITHELIAL-MESENCHYMAL TRANSITION RS Oncology, LLC (US) 2026-02-18 EP claimed
EP-0563507-B1 Transdermal patch incorporating a polymer film incorporated with an active agent BERTEK INC (US) 1998-05-27 EP claimed
US-5681737-A USING SALMONELLA STRAINS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1997-10-28 US claimed
US-5679373-A MELT-BLENDING THERMOPLASTIC MATRIX; IMPERMEABLE BACKING; LAMINATION WITHOUT ADHESIVE; CONTROLLED RELEASE BERTEK, INC. (US) 1997-10-21 US claimed
WO-1997033611-A1 METHOD OF KILLING TARGET CELLS IN HARVESTED CELL POPULATIONS WITH ONE OR MORE IMMUNOTOXINS FODSTAD OEYSTEIN (NO) 1997-09-18 WO claimed
US-5662926-A SOLVENT FREE BERTEK, INC. (US) 1997-09-02 US claimed
EP-0723597-A1 A DETECTION SYSTEM FOR MUTAGENS THAT ALSO IDENTIFIES MUTAGENIC CHANGES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1996-07-31 EP claimed
EP-0652231-A1 NON-TOXIC RIBOSOME INACTIVATING PROTEINS (RIPs) WITH TWO CHAINS, PROCESS FOR THE PREPARATION THEREOF AND APPLICATIONS UNIVERSIDAD DE VALLADOLID (ES) 1995-05-10 EP claimed
WO-1995010629-A1 A DETECTION SYSTEM FOR MUTAGENS THAT ALSO IDENTIFIES MUTAGENIC CHANGES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1995-04-20 WO claimed
EP-0563507-A1 Transdermal patch incorporating a polymer film incorporated with an active agent MLI ACQUISITION CORP. II (US) 1993-10-06 EP claimed
EP-0227593-A1 Use of chelating agents THE HOSPITAL FOR SICK CHILDREN (CA) 1987-07-01 EP claimed